Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clon.2014.03.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Int J Radiat Oncol Biol Phys
July 2024
Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom. Electronic address:
Purpose: Tumor hypoxia is an adverse prognostic factor in head and neck squamous cell carcinoma (HNSCC). We assessed whether patients with hypoxic HNSCC benefited from the addition of nimorazole to definitive intensity modulated radiation therapy (IMRT).
Methods And Materials: NIMRAD was a phase 3, multicenter, placebo-controlled, double-anonymized trial of patients with HNSCC unsuitable for concurrent platinum chemotherapy or cetuximab with definitive IMRT (NCT01950689).
Accumulating long-term evidence for partial breast irradiation.
Lancet Oncol
March 2023
Department of Oncology, University of Cambridge, Cambridge, UK.
NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
Clin Oncol (R Coll Radiol)
June 2014
Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!